Psyence Biomedical (NASDAQ:PBM – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.24) EPS for the quarter, FiscalAI reports.
Psyence Biomedical Price Performance
NASDAQ PBM opened at $2.86 on Friday. The company’s 50 day simple moving average is $4.41 and its 200 day simple moving average is $3.87. Psyence Biomedical has a 12 month low of $1.92 and a 12 month high of $16.96. The company has a market capitalization of $6.56 million, a P/E ratio of 0.11 and a beta of 1.72.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on PBM. Wall Street Zen upgraded Psyence Biomedical to a “hold” rating in a report on Saturday, October 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Psyence Biomedical in a report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has a consensus rating of “Sell”.
Check Out Our Latest Stock Analysis on PBM
Psyence Biomedical Company Profile
Psyence Biomedical Ltd. is a clinical-stage biopharmaceutical company developing nature-derived psychedelic treatments for mental health and palliative care. Its research focuses on psilocybin, a psychedelic compound, for potential use in supervised therapeutic settings. The company’s lead candidate, PEX010, is a naturally derived psilocybin product being studied for adjustment disorder in people receiving palliative care. Psyence Biomedical’s work centers on clinical development and evaluating the safety and potential therapeutic effects of this treatment.
Read More
- Five stocks we like better than Psyence Biomedical
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
Receive News & Ratings for Psyence Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psyence Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
